Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Julie Milojevic"'
Autor:
Edwin Wong, Carla Nester, Teresa Cavero, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Ute Eisenberger, Maria Jose Soler, David Kavanagh, Erica Daina, Manuel Praga, Nicholas R. Medjeral-Thomas, Anja Gäckler, Clara Garcia-Carro, Andrea Biondani, Frederique Chaperon, Kenneth Kulmatycki, Julie Milojevic, Nicholas J.A. Webb, Prasanna Kumar Nidamarthy, Guido Junge, Giuseppe Remuzzi
Publikováno v:
Kidney International Reports, Vol 8, Iss 12, Pp 2754-2764 (2023)
Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability,
Externí odkaz:
https://doaj.org/article/4142dfa19bbe4b318478e3240af7c53c
Autor:
Antonio Risitano, Régis Peffault de Latour, Eng Soo Yap, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Alexander Roeth, Irina Baltcheva, Julie Milojevic, Niamh Fagan, Kenneth Kulmatycki, Prasanna K Nidamarthy, Guido Junge, Jun Ho Jang
Publikováno v:
Blood. 140:5803-5804
Autor:
Jose Alcantara, Kenneth Kulmatycki, David J. Rowlands, Nicholas J. Simmonds, Lidia Mostovy, Surendra Machineni, Ivan Bottoli, Phaninatha Sarma Ayalavajjala, Robert M. Strieter, Henry Danahay, Shamsah Kazani, Raju Vegesna, Jerry A. Nick, Ieuan Jones, Mohammed Salman, Steven M. Rowe, Ian Nicholls, Martin Gosling, Julie Milojevic, Jeroen Verheijen
Publikováno v:
Journal of Cystic Fibrosis. 20:250-256
Background This is the first-in-human study of icenticaftor, an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel. Restoration of CFTR activity has shown significant clinical benefits, but more studies ar
Autor:
Benjamin A Fisher, Michele Bombardieri, Hans-Ulrich Hockey, Antónia Szántó, Andrew M Wright, Athena Papas, Michael Rotte, Alexandre Avrameas, David A. Isenberg, Bettina Bannert, Pascal Espie, Cyrielle Dupuy, Steven E. Carsons, Diego Kyburz, Maximilian G. Posch, Marie-Anne Valentin, Julie Milojevic, Francesca Barone, Petra M Faerber, Simon J Bowman, Arwa M. Farag, Thomas Daikeler, Xiaohui Ren, Peter Gergely, David Floch, Wan-Fai Ng, James S. Rush, Alan Kivitz
Publikováno v:
The Lancet Rheumatology. 2:e142-e152
Summary Background Primary Sjogren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary Sjogren's syndrome have shown efficacy
Autor:
Ralph Woessner, Rachel Soon, Claudio Calonder, Julie Milojevic, Bruno Boutouyrie-Dumont, David M. Pariser, Irina Koroleva, Anke Hasselberg, Gerard Bruin
Publikováno v:
Clinical Pharmacology and Therapeutics
This open‐label disease‐drug–drug interaction study assessed whether blockade of the interleukin (IL)‐17A pathway by secukinumab and subsequent downregulation of inflammatory cytokines like IL‐6 or high‐sensitivity C‐reactive protein af
Autor:
Yue Li, Claudia Simonett, Esther Kamphausen, Louise Mooney, Stephen John Oliver, Maciej Cabanski, Thomas Dörner, Andreas Hüser, Olivier Petricoul, Frank Wagner, Marie-Anne Valentin, Hermann Gram, Julie Milojevic, Maximilian G. Posch
Publikováno v:
Annals of the Rheumatic Diseases. 78:641-647
ObjectivesTo evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) in a double-blind, placebo-controlle
Autor:
Régis Peffault de Latour, Alexander Röth, Prasanna Kumar Nidamarthy, Camilla Frieri, Izabela Rozenberg, Antonio M. Risitano, Peter End, Juliette Soret, Serena Marotta, Flore Sicre de Fontbrune, Ferras Alashkar, Lina Benajiba, Guido Junge, Luana Marano, Julie Milojevic
The haematological benefit of standard-of-care anti-C5 treatment for haemolytic paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or emerging C3-mediated extravascular haemolysis. Therefore, the aim of this phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::669b69dedf0847b0e54cfa115d20af1e
https://www.ncbi.nlm.nih.gov/pubmed/33765419
https://www.ncbi.nlm.nih.gov/pubmed/33765419
Autor:
Thomas Holbro, Haraldsson Boerje, Nicholas Webb, Peter End, Anna Schubart, Guido Junge, Julie Milojevic
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims The alternative complement pathway (AP) provides the central amplification loop of complement activation and is critically involved in a number of diseases including C3 glomerulopathy (C3G), paroxysmal nocturnal haemoglobinuria (P
Autor:
Roland Schuler, Michael Rotte, Yan-Ling He, Peter Gergely, Pascal Espie, Laurence Colin, Anita Auger, Heidi Mergentaler, Martha Hernandez‐Illas, James S. Rush, Jacinda Ristov, Julie Milojevic, Denise Sickert, Cyrielle Dupuy, Alexandre Avrameas, Edwige Chokote, Phillip Koo, Aurelie Verles, Andrea Groenewegen, Charles S. Tomek
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsReferences. 20(2)
Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability